Safety and Efficacy of CD10367 in Psoriasis Vulgaris
Status:
Completed
Trial end date:
2017-03-24
Target enrollment:
Participant gender:
Summary
This is an exploratory, single-centre, investigator blinded, randomized, controlled,
intra-individual study, involving subjects with psoriasis vulgaris.
The objective is to evaluate, in a modified Dumas-Scholtz psoriasis mini-zone test, the
safety and efficacy of CD10367 solution at 1% and 3% after a 3-week treatment period of once
daily application.